Alterity Therapeutics Phase 2 Data Monitoring Committee
ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 Top-Line Data Expected by the End of 2024 MELBOURNE, Australia and SAN FRANCISCO, July 26,...
Source: globenewswire.com
Page 20 - Multiple System Atrophy News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Multiple System Atrophy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Multiple System Atrophy Today - Breaking & Trending Today
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned
ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 Top-Line Data Expected by the End of 2024 MELBOURNE, Australia and SAN FRANCISCO, July 26, 2023 -- Alterity Therapeutics , a...
Source: marketscreener.com
Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson's Patients
Disease-modifying candidate UB-312 demonstrated target engagement of aggregated alpha-synuclein in cerebrospinal fluid of Parkinson’s patients Data provide validation of the Vaxxinity platform’s...
Source: marketscreener.com
Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements
/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase...
Source: prnewswire.com
Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements
BOSTON and ATLANTA, July 17, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of...
Source: marketscreener.com